Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
July 25th, 2025 7:48 PM
By: Advos Staff Reporter
Soligenix Inc. is developing SGX945, a promising therapy for Behçet’s disease, addressing a critical unmet need in rare disease treatment.

Soligenix Inc. (NASDAQ: SNGX) is making strides in the treatment of Behçet’s disease, a rare autoimmune condition with significant impacts on quality of life. The company's investigational drug, SGX945, aims to modulate the body’s innate immune response, offering hope for a more targeted and effective therapy. Behçet’s disease, characterized by severe symptoms in young adulthood, currently lacks treatments that fully address its complications without adverse effects.
The development of SGX945 is part of Soligenix’s broader mission to tackle unmet medical needs in rare diseases. Preclinical studies have shown the drug’s potential in reducing inflammation and promoting tissue healing, marking a significant step forward in rare disease therapeutics. This advancement not only highlights Soligenix’s commitment to innovative healthcare solutions but also underscores the importance of addressing rare conditions that have been historically underserved by the pharmaceutical industry.
For more information on Soligenix’s efforts and the potential impact of SGX945, visit https://ibn.fm/lyFjD.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
